𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Monotherapy versus combined androgen blockade in patients with advanced prostate cancer

✍ Scribed by Abelardo Errejon; E. David Crawford

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
33 KB
Volume
95
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Despite a number of large randomized clinical trials, there still is uncertainty regarding the value of maximal androgen blockade in the treatment of patients with advanced prostate carcinoma. In the referenced article, the authors provide a very comprehensive review of the literature concerning one of the most controversial issues in contemporary urology.

See also pages 361–76.

πŸ“œ SIMILAR VOLUMES

Systematic review and meta-analysis of m
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
✍ David J. Samson; Jerome Seidenfeld; Brian Schmitt; Vic Hasselblad; Peter C. Albe πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The current systematic review and meta‐analysis compared monotherapy and combined androgen blockade in the treatment of men with advanced prostate carcinoma. Outcomes of interest included overall, cancer specific, and progression‐free survival; time to treatment failure;

Twenty years of controversy surrounding
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer
✍ Judd W. Moul πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 71 KB

The current issue of __Cancer__ includes a report on a concise, randomized controlled trial (RCT) with long‐term follow‐up that favors combined androgen blockade with bicalutamide versus lutenizing hormone‐releasing hormone monotherapy in Japanese men with locally advanced and metastatic prostate ca

Development of anemia and recovery in pr
Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy
✍ Asbell, S. O.; Leon, S. A.; Tester, W. J.; Brereton, H. D.; Ago, C. T.; Rotman, πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 488 KB πŸ‘ 2 views

## BACKGROUND. The objective of this study was to document previously unreported anemia in prostate cancer patients treated with neoadjuvant combined androgen blockade (CAB) and pelvic radiotherapy (XRT). METHODS. Four institutions treated 141 patients (mean age f SD, 70.9 ? 6.5 years) with zolad

IncreasedRB1 abnormalities in human prim
IncreasedRB1 abnormalities in human primary prostate cancer following combined androgen blockade
✍ Mack, Philip C.; Chi, Sung-Gil; Meyers, Frederick J.; Stewart, Susan L.; deVere πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 196 KB

BACKGROUND. The RB1 proliferation control pathway is a critical determinant of cell cycle progression. Abnormalities of RB1 are found in a variety of cancers, and the association with human prostate cancer (CaP) was examined here. METHODS. RNA expression levels of RB1 in CaPs were examined by RT-PCR